Tocilizumab or sarilumab are equally suitable for treatment of COVID-19, new advice says

摘要

The Royal Pharmaceutical Society has made this article free to access in order to help healthcare professionals support patients during the COVID-19 pandemic. For more information, visit:?https://www.rpharms.com/coronavirus (https://www.rpharms.com/coronavirus) Tocilizumab or sarilumab are equally suitable to treat adult patients hospitalised with COVID-19, according to the latest advice from health ocials.